
J&J reports positive results for Tremfya
Johnson & Johnson has reported positive results for its Phase III FUZION study of its Tremfya (guselkumab) therapy for Crohn’s disease. The findings show that Tremfya maintained or improved fistula remission through 48 weeks in adults with Crohn’s disease. Johnson & Johnson state the findings, which are… Read More










